ROIV
NASDAQ · Biotechnology
Roivant Sciences Ltd
$36.13
-0.69 (-1.87%)
Financial Highlights (FY 2026)
Revenue
8.54M
Net Income
-309,925,055
Gross Margin
84.4%
Profit Margin
-3,629.2%
Rev Growth
-48.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 84.4% | 84.4% | 53.5% | 53.5% |
| Operating Margin | -6,102.2% | -5,492.0% | -4.7% | -4.6% |
| Profit Margin | -3,629.2% | -3,447.7% | -5.1% | -4.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 8.54M | 16.65M | 2.76B | 2.29B |
| Gross Profit | 7.21M | 14.06M | 1.47B | 1.22B |
| Operating Income | -520,961,473 | -914,502,293 | -129,388,409 | -105,547,959 |
| Net Income | -309,925,055 | -544,046,322 | -140,854,131 | -104,632,272 |
| Gross Margin | 84.4% | 84.4% | 53.5% | 53.5% |
| Operating Margin | -6,102.2% | -5,492.0% | -4.7% | -4.6% |
| Profit Margin | -3,629.2% | -3,447.7% | -5.1% | -4.6% |
| Rev Growth | -48.7% | -48.7% | -1.7% | -7.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 7.19B | 7.29B |
| Total Equity | — | — | 12.91B | 14.47B |
| D/E Ratio | — | — | 0.56 | 0.50 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -517,689,629 | -959,245,460 | -182,068,335 | -161,653,425 |
| Free Cash Flow | — | — | -125,369,781 | -83,019,830 |